Novelties in Research and Treatments of Pancreatic Cancers
Speaker: Thomas Seufferlein
- Biology of pancreatic cancers
- What is a mechanism of action of novel drugs IMM 101 and PEGPH20?
- Results from a phase II trial of gemcitabine with and without IMM 101 in advanced pancreatic cancer (abstract O-0003)
- Results from a phase II trial of PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumours (abstract LBA-02)
- Other new agents/strategies on the horizon for pancreatic cancer